{"id":10438,"date":"2026-08-12T09:00:00","date_gmt":"2026-08-12T15:00:00","guid":{"rendered":"https:\/\/www.podermexico.mx\/?p=10438"},"modified":"2026-08-12T08:19:53","modified_gmt":"2026-08-12T14:19:53","slug":"cofepris-aprueba-el-tratamiento-nipocalimab-para-el-control-de-la-miastenia-gravis-generalizada","status":"publish","type":"post","link":"https:\/\/www.podermexico.mx\/?p=10438","title":{"rendered":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (<a href=\"https:\/\/www.podermexico.mx\/?s=Cofepris\" title=\"\">Cofepris<\/a>) aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma Johnson &amp; Johnson para el tratamiento de la miastenia gravis generalizada. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La terapia g\u00e9nica est\u00e1 indicada para adultos y adolescentes mayores de <strong>12<\/strong> a\u00f1os que presentan anticuerpos espec\u00edficos asociados a esta condici\u00f3n neuromuscular, la cual afecta la comunicaci\u00f3n entre nervios y m\u00fasculos dificultando funciones como respirar, hablar o tragar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La resoluci\u00f3n sanitaria se fundamenta en los resultados del ensayo cl\u00ednico internacional de fase <strong>3<\/strong> denominado Vivacity-MG3, realizado en <strong>199<\/strong> pacientes. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La evaluaci\u00f3n m\u00e9dica de demostr\u00f3 que la administraci\u00f3n de esta mol\u00e9cula reduce hasta <strong>75%<\/strong> los niveles de autoanticuerpos desde la primera dosis y mantiene el control sostenido de los s\u00edntomas durante <strong>96<\/strong> semanas. El f\u00e1rmaco cuenta con la aprobaci\u00f3n previa de las autoridades regulatorias en <strong>11<\/strong> pa\u00edses y regiones, incluyendo Estados Unidos, China y la Uni\u00f3n Europea<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma Johnson &amp; Johnson para el tratamiento de la miastenia gravis generalizada. La terapia g\u00e9nica est\u00e1 indicada para adultos y adolescentes mayores de 12 a\u00f1os que presentan anticuerpos espec\u00edficos asociados a esta condici\u00f3n neuromuscular, la cual afecta la comunicaci\u00f3n entre nervios &hellip;<\/p>\n","protected":false},"author":7,"featured_media":10439,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[1319,134],"class_list":["post-10438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-salud","tag-cofepris","tag-salud"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Poder M\u00e9xico\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.podermexico.mx\/?p=10438\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"es_MX\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Poder M\u00e9xico - Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico\" \/>\n\t\t<meta property=\"og:description\" content=\"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.podermexico.mx\/?p=10438\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-12T15:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-12T14:19:53+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#blogposting\",\"name\":\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\\u00e9xico\",\"headline\":\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada\",\"author\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/asf-detecta-irregularidades-contratos-cofepris.jpeg\",\"width\":1200,\"height\":807},\"datePublished\":\"2026-08-12T09:00:00-06:00\",\"dateModified\":\"2026-08-12T08:19:53-06:00\",\"inLanguage\":\"es-MX\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#webpage\"},\"articleSection\":\"Salud, Cofepris, Salud\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.podermexico.mx\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"name\":\"Salud\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"position\":2,\"name\":\"Salud\",\"item\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#listItem\",\"name\":\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#listItem\",\"position\":3,\"name\":\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?cat=68#listItem\",\"name\":\"Salud\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\",\"name\":\"Poder M\\u00e9xico\",\"description\":\"Donde los l\\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\\u00edtica y los negocios\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7\",\"name\":\"Poder M\\u00e9xico\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6873d270747c7f511ab0e491b4ef59ff185c68a5912118c90f83cdcd498e434b?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Poder M\\u00e9xico\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#webpage\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438\",\"name\":\"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\\u00e9xico\",\"description\":\"Cofepris aprob\\u00f3 la comercializaci\\u00f3n del medicamento nipocalimab, desarrollado por la firma J&J para el tratamiento de la miastenia gravis generalizada.\",\"inLanguage\":\"es-MX\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?author=7#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/asf-detecta-irregularidades-contratos-cofepris.jpeg\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438\\\/#mainImage\",\"width\":1200,\"height\":807},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/?p=10438#mainImage\"},\"datePublished\":\"2026-08-12T09:00:00-06:00\",\"dateModified\":\"2026-08-12T08:19:53-06:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#website\",\"url\":\"https:\\\/\\\/www.podermexico.mx\\\/\",\"name\":\"Poder M\\u00e9xico\",\"description\":\"Donde los l\\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\\u00edtica y los negocios\",\"inLanguage\":\"es-MX\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.podermexico.mx\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico","description":"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&J para el tratamiento de la miastenia gravis generalizada.","canonical_url":"https:\/\/www.podermexico.mx\/?p=10438","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.podermexico.mx\/?p=10438#blogposting","name":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico","headline":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada","author":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"publisher":{"@id":"https:\/\/www.podermexico.mx\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.podermexico.mx\/wp-content\/uploads\/2026\/08\/asf-detecta-irregularidades-contratos-cofepris.jpeg","width":1200,"height":807},"datePublished":"2026-08-12T09:00:00-06:00","dateModified":"2026-08-12T08:19:53-06:00","inLanguage":"es-MX","mainEntityOfPage":{"@id":"https:\/\/www.podermexico.mx\/?p=10438#webpage"},"isPartOf":{"@id":"https:\/\/www.podermexico.mx\/?p=10438#webpage"},"articleSection":"Salud, Cofepris, Salud"},{"@type":"BreadcrumbList","@id":"https:\/\/www.podermexico.mx\/?p=10438#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx#listItem","position":1,"name":"Home","item":"https:\/\/www.podermexico.mx","nextItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","name":"Salud"}},{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","position":2,"name":"Salud","item":"https:\/\/www.podermexico.mx\/?cat=68","nextItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?p=10438#listItem","name":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?p=10438#listItem","position":3,"name":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada","previousItem":{"@type":"ListItem","@id":"https:\/\/www.podermexico.mx\/?cat=68#listItem","name":"Salud"}}]},{"@type":"Organization","@id":"https:\/\/www.podermexico.mx\/#organization","name":"Poder M\u00e9xico","description":"Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","url":"https:\/\/www.podermexico.mx\/"},{"@type":"Person","@id":"https:\/\/www.podermexico.mx\/?author=7#author","url":"https:\/\/www.podermexico.mx\/?author=7","name":"Poder M\u00e9xico","image":{"@type":"ImageObject","@id":"https:\/\/www.podermexico.mx\/?p=10438#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/6873d270747c7f511ab0e491b4ef59ff185c68a5912118c90f83cdcd498e434b?s=96&d=mm&r=g","width":96,"height":96,"caption":"Poder M\u00e9xico"}},{"@type":"WebPage","@id":"https:\/\/www.podermexico.mx\/?p=10438#webpage","url":"https:\/\/www.podermexico.mx\/?p=10438","name":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico","description":"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&J para el tratamiento de la miastenia gravis generalizada.","inLanguage":"es-MX","isPartOf":{"@id":"https:\/\/www.podermexico.mx\/#website"},"breadcrumb":{"@id":"https:\/\/www.podermexico.mx\/?p=10438#breadcrumblist"},"author":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"creator":{"@id":"https:\/\/www.podermexico.mx\/?author=7#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.podermexico.mx\/wp-content\/uploads\/2026\/08\/asf-detecta-irregularidades-contratos-cofepris.jpeg","@id":"https:\/\/www.podermexico.mx\/?p=10438\/#mainImage","width":1200,"height":807},"primaryImageOfPage":{"@id":"https:\/\/www.podermexico.mx\/?p=10438#mainImage"},"datePublished":"2026-08-12T09:00:00-06:00","dateModified":"2026-08-12T08:19:53-06:00"},{"@type":"WebSite","@id":"https:\/\/www.podermexico.mx\/#website","url":"https:\/\/www.podermexico.mx\/","name":"Poder M\u00e9xico","description":"Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","inLanguage":"es-MX","publisher":{"@id":"https:\/\/www.podermexico.mx\/#organization"}}]},"og:locale":"es_MX","og:site_name":"Poder M\u00e9xico - Donde los l\u00edderes definen el futuro, exploramos tendencias y desciframos el mundo de la pol\u00edtica y los negocios","og:type":"article","og:title":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico","og:description":"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada.","og:url":"https:\/\/www.podermexico.mx\/?p=10438","article:published_time":"2026-08-12T15:00:00+00:00","article:modified_time":"2026-08-12T14:19:53+00:00","twitter:card":"summary_large_image","twitter:title":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada - Poder M\u00e9xico","twitter:description":"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada."},"aioseo_meta_data":{"post_id":"10438","title":null,"description":"Cofepris aprob\u00f3 la comercializaci\u00f3n del medicamento nipocalimab, desarrollado por la firma J&amp;J para el tratamiento de la miastenia gravis generalizada.","keywords":null,"keyphrases":{"focus":{"keyphrase":"Cofepris","score":0,"analysis":[]},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-08-12 14:16:26","updated":"2026-08-12 14:19:53","seo_analyzer_scan_date":null,"focus_keyword":"Cofepris","additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.podermexico.mx\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.podermexico.mx\/?cat=68\" title=\"Salud\">Salud<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tCofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.podermexico.mx"},{"label":"Salud","link":"https:\/\/www.podermexico.mx\/?cat=68"},{"label":"Cofepris aprueba el tratamiento nipocalimab para el control de la miastenia gravis generalizada","link":"https:\/\/www.podermexico.mx\/?p=10438"}],"_links":{"self":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/10438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10438"}],"version-history":[{"count":1,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/10438\/revisions"}],"predecessor-version":[{"id":10440,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/posts\/10438\/revisions\/10440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=\/wp\/v2\/media\/10439"}],"wp:attachment":[{"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.podermexico.mx\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}